Determination of aluminium induced metabolic changes in mice liver: A Fourier transform infrared spectroscopy study.
In this study, we made a new approach to evaluate aluminium induced metabolic changes in liver tissue of mice using Fourier transform infrared spectroscopy analysis taking one step further in correlation with strong biochemical evidence.
This finding reveals the alterations on the major biochemical constituents, such as lipids, proteins, nucleic acids and glycogen of the liver tissues of mice. The peak area value of amide A significantly decrease from 288.278±3.121 to 189.872±2.012 between control and aluminium treated liver tissue respectively.
Amide I and amide II peak area value also decrease from 40.749±2.052 to 21.170±1.311 and 13.167±1.441 to 8.953±0.548 in aluminium treated liver tissue respectively. This result suggests an alteration in the protein profile.
The absence of olefinicCH stretching band and CO stretching of triglycerides in aluminium treated liver suggests an altered lipid levels due to aluminium exposure. Significant shift in the peak position of glycogen may be the interruption of aluminium in the calcium metabolism and the reduced level of calcium.
The overall findings exhibit that the liver metabolic program is altered through increasing the structural modification in proteins, triglycerides and quantitative alteration in proteins, lipids, and glycogen. All the above mentioned modifications were protected in desferrioxamine treated mice.
Histopathological results also revealed impairment of aluminium induced alterations in liver tissue. The results of the FTIR study were found to be in agreement with biochemical studies and which demonstrate FTIR can be used successfully to indicate the molecular level changes.
Sivakumar S, Sivasubramanian J, Khatiwada CP, Manivannan J, Raja B. Spectrochim Acta A Mol Biomol Spectrosc. 2013 Mar 21;110C:241-248. doi: 10.1016/j.saa.2013.03.056
Department of Physics, Annamalai University, Annamalai Nagar 608 002, Tamil Nadu, India. Electronic address: email@example.com.
About desferrioxamine, a chelating agent to get rid of excess iron or other metals in the bodyDesferal injections contain the active ingredient desferrixoamine mesilate, which is a type of medicine called a chelating agent.
Desferrioxamine is a medicine that binds to excess iron in the body. It is then excreted in the urine and faeces, thereby reducing iron levels in the body.
Iron is an essential part of haemoglobin, the oxygen-carrying pigment found in red blood cells. In normal situations, iron balance is tightly controlled. Most average diets supply adequate amounts of iron and any amounts excess to requirements are excreted. In certain circumstances, the normal control mechanisms are overwhelmed, leading to an accumulation of iron in the body (iron overload). Iron builds up in the cells of the kidneys, heart, liver, brain and other organs, and can cause congestive heart failure, cirrhosis of the liver and diabetes if left untreated.
Iron overload occurs most commonly as a result of repeated blood transfusions. These might be necessary to treat bone marrow failure (eg caused by radiation, chemotherapy, viruses or hereditary reasons) or blood disorders like thalassaemia or anaemias. Or it may be as a result of iron storage disease, eg haemochromatosis. In this condition, excessive amounts of iron are absorbed from the gut and deposited in the tissues.
Iron overload can also occur as the result of iron overdosage (iron poisoning).
Desferrioxamine is given to bind to and remove excess iron in all these situations.
Connie’s comments: Alzheimer’s and Parkinson’s diseases are believed to be be caused by metal toxins such as aluminum. Use stainless steel cooking pots and pans.
Connie Dello Buono
Connie Dello Buono ; firstname.lastname@example.org
Call for part time or full time business or job 408-854-1883 in financial planning, college planning, retirement planning and helping others with their idle money to work for them at 13%, tax free, safe and secured with free health benefits